Surrey Clinical Research Centre has signed a new five-year renewal contract to use Promasys EDC from OmniComm Systems, Inc. Surrey Clinical Research, an MHRA Phase I accredited facility with expertise in Phase I, first-in-human, through to Phase IV, has used Promasys since 2014, and the new agreement extends that commitment for an additional five-year period from 2019 to 2024. Surrey CRC is able to advise and execute the complete clinical trials process from start to finish, including protocol design and development, oversight of all regulatory applications, set-up, management and conduct, as well as data management, data analysis and reporting from single-site to global multi-center trials. The enhanced features and functionality of Promasys 7.4 include improvements to the Lab Connector, Lab Review Module, Sample Tracking, Event Coding and Electronic Signatures — all of which were instrumental in securing the new agreement with Surrey. In addition, PRO workflow capabilities were an added bonus, as Surrey is looking to incorporate patient-reported outcomes in upcoming studies.